{
  "pmcid": "4029101",
  "sha256": "5a8ab5b2fb94325c9aa7fdbe3abfb2ba46f0ed7eb2d68d34ddcf1e7c68215f49",
  "timestamp_utc": "2025-11-09T15:56:58.581538+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.990315430520035,
    "reading_ease": 38.01487212276217,
    "word_count": 276
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "in a prospective multicenter phase II study of adult solid organ transplant recipients"
      },
      "Participants": {
        "score": 2,
        "evidence": "16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for 1 week if not in complete remission (CR)."
      },
      "Objective": {
        "score": 1,
        "evidence": "We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Twenty patients were registered over 60 months"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "16 patients with biopsy-proven PTLD were eligible"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years."
      },
      "Harms": {
        "score": 1,
        "evidence": "Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}